{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:01:38Z","timestamp":1791428498298,"version":"4.3.3"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1038\/s41577-020-00460-4","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T11:02:54Z","timestamp":1601982174000},"page":"709-713","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":249,"title":["Cross-reactive memory T cells and herd immunity to SARS-CoV-2"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1504-9213","authenticated-orcid":false,"given":"Marc","family":"Lipsitch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonatan H.","family":"Grad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Sette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6484-6262","authenticated-orcid":false,"given":"Shane","family":"Crotty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"key":"460_CR1","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41577-020-0389-z","volume":"20","author":"A Sette","year":"2020","unstructured":"Sette, A. & Crotty, S. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. Nat. Rev. Immunol. 20, 457\u2013458 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"460_CR2","doi-asserted-by":"publisher","first-page":"m3563","DOI":"10.1136\/bmj.m3563","volume":"370","author":"P Doshi","year":"2020","unstructured":"Doshi, P. Covid-19: do many people have pre-existing immunity? BMJ 370, m3563 (2020).","journal-title":"BMJ"},{"key":"460_CR3","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1126\/science.abb5793","volume":"368","author":"SM Kissler","year":"2020","unstructured":"Kissler, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H. & Lipsitch, M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science 368, 860\u2013868 (2020).","journal-title":"Science"},{"key":"460_CR4","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489\u20131501.e15 (2020).","journal-title":"Cell"},{"key":"460_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2598-9","author":"J Braun","year":"2020","unstructured":"Braun, J. et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature https:\/\/doi.org\/10.1038\/s41586-020-2598-9 (2020).","journal-title":"Nature"},{"key":"460_CR6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","volume":"584","author":"NL Bert","year":"2020","unstructured":"Bert, N. L. et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 584, 457\u2013462 (2020).","journal-title":"Nature"},{"key":"460_CR7","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd3871","author":"J Mateus","year":"2020","unstructured":"Mateus, J. et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science https:\/\/doi.org\/10.1126\/science.abd3871 (2020).","journal-title":"Science"},{"key":"460_CR8","doi-asserted-by":"publisher","first-page":"eabd2071","DOI":"10.1126\/sciimmunol.abd2071","volume":"5","author":"D Weiskopf","year":"2020","unstructured":"Weiskopf, D. et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci. Immunol. 5, eabd2071 (2020).","journal-title":"Sci. Immunol."},{"key":"460_CR9","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.12.148916","author":"BJ Meckiff","year":"2020","unstructured":"Meckiff, B. J. et al. Single-cell transcriptomic analysis of SARS-CoV-2 reactive CD4+ T cells. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.06.12.148916 (2020).","journal-title":"bioRxiv"},{"key":"460_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.017","author":"T Sekine","year":"2020","unstructured":"Sekine, T. et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell https:\/\/doi.org\/10.1016\/j.cell.2020.08.017 (2020).","journal-title":"Cell"},{"key":"460_CR11","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/ni.3031","volume":"15","author":"JT Chang","year":"2014","unstructured":"Chang, J. T., Wherry, E. J. & Goldrath, A. W. Molecular regulation of effector and memory T cell differentiation. Nat. Immunol. 15, 1104\u20131115 (2014).","journal-title":"Nat. Immunol."},{"key":"460_CR12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1146\/annurev-immunol-042617-053214","volume":"37","author":"D Masopust","year":"2019","unstructured":"Masopust, D. & Soerens, A. G. Tissue-resident T cells and other resident leukocytes. Annu. Rev. Immunol. 37, 521\u2013546 (2019).","journal-title":"Annu. Rev. Immunol."},{"key":"460_CR13","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","volume":"50","author":"S Crotty","year":"2019","unstructured":"Crotty, S. T follicular helper cell biology: a decade of discovery and diseases. Immunity 50, 1132\u20131148 (2019).","journal-title":"Immunity"},{"key":"460_CR14","doi-asserted-by":"publisher","first-page":"100040","DOI":"10.1016\/j.xcrm.2020.100040","volume":"1","author":"MS Suthar","year":"2020","unstructured":"Suthar, M. S. et al. Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Rep. Med. 1, 100040 (2020).","journal-title":"Cell Rep. Med."},{"key":"460_CR15","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41591-020-0913-5","volume":"26","author":"F Amanat","year":"2020","unstructured":"Amanat, F. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 26, 1033\u20131036 (2020).","journal-title":"Nat. Med."},{"key":"460_CR16","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","volume":"38","author":"CW Tan","year":"2020","unstructured":"Tan, C. W. et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2\u2013spike protein\u2013protein interaction. Nat. Biotechnol. 38, 1073\u20131078 (2020).","journal-title":"Nat. Biotechnol."},{"key":"460_CR17","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.3201\/eid2607.200841","volume":"26","author":"NMA Okba","year":"2020","unstructured":"Okba, N. M. A. et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease 2019 patients. Emerg. Infect. Dis. 26, 1478\u20131488 (2020).","journal-title":"Emerg. Infect. Dis."},{"key":"460_CR18","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1126\/science.abc7424","volume":"369","author":"AZ Wec","year":"2020","unstructured":"Wec, A. Z. et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science 369, 731\u2013736 (2020).","journal-title":"Science"},{"key":"460_CR19","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00089-20","volume":"94","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. T cell responses induced by attenuated flavivirus vaccination are specific and show limited cross-reactivity with other flavivirus species. J. Virol. 94, e00089-20 (2020).","journal-title":"J. Virol."},{"key":"460_CR20","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1073\/pnas.1314688110","volume":"111","author":"JM Warfel","year":"2014","unstructured":"Warfel, J. M., Zimmerman, L. I. & Merkel, T. J. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc. Natl Acad. Sci. USA 111, 787\u2013792 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"460_CR21","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1126\/science.abc6284","volume":"369","author":"J Yu","year":"2020","unstructured":"Yu, J. et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369, 806\u2013811 (2020).","journal-title":"Science"},{"key":"460_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2608-y","author":"N van Doremalen","year":"2020","unstructured":"Doremalen, N. van et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature https:\/\/doi.org\/10.1038\/s41586-020-2608-y (2020).","journal-title":"Nature"},{"key":"460_CR23","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/nm.2612","volume":"18","author":"TM Wilkinson","year":"2012","unstructured":"Wilkinson, T. M. et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 18, 274\u2013280 (2012).","journal-title":"Nat. Med."},{"key":"460_CR24","doi-asserted-by":"publisher","first-page":"20365","DOI":"10.1073\/pnas.0911580106","volume":"106","author":"JA Greenbaum","year":"2009","unstructured":"Greenbaum, J. A. et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc. Natl Acad. Sci. USA 106, 20365\u201320370 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"460_CR25","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/nm.3350","volume":"19","author":"S Sridhar","year":"2013","unstructured":"Sridhar, S. et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med. 19, 1305\u20131312 (2013).","journal-title":"Nat. Med."},{"key":"460_CR26","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s41591-020-0869-5","volume":"26","author":"X He","year":"2020","unstructured":"He, X. et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat. Med. 26, 672\u2013675 (2020).","journal-title":"Nat. Med."},{"key":"460_CR27","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1126\/science.1086616","volume":"300","author":"M Lipsitch","year":"2003","unstructured":"Lipsitch, M. et al. Transmission dynamics and control of severe acute respiratory syndrome. Science 300, 1966\u20131970 (2003).","journal-title":"Science"},{"key":"460_CR28","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nature04153","volume":"438","author":"JO Lloyd-Smith","year":"2005","unstructured":"Lloyd-Smith, J. O., Schreiber, S. J., Kopp, P. E. & Getz, W. M. Superspreading and the effect of individual variation on disease emergence. Nature 438, 355\u2013359 (2005).","journal-title":"Nature"},{"key":"460_CR29","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.immuni.2016.05.006","volume":"44","author":"J Zhao","year":"2016","unstructured":"Zhao, J. et al. Airway memory CD4+ T cells mediate protective immunity against emerging respiratory coronaviruses. Immunity 44, 1379\u20131391 (2016).","journal-title":"Immunity"},{"key":"460_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0966-842X(97)81772-6","volume":"5","author":"M Lipsitch","year":"1997","unstructured":"Lipsitch, M. & Moxon, E. R. Virulence and transmissibility of pathogens: what is the relationship? Trends Microbiol. 5, 31\u201337 (1997).","journal-title":"Trends Microbiol."},{"key":"460_CR31","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.4049\/jimmunol.1102243","volume":"187","author":"JR Teijaro","year":"2011","unstructured":"Teijaro, J. R. et al. Cutting edge: Tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection. J. Immunol. 187, 5510\u20135514 (2011).","journal-title":"J. Immunol."},{"key":"460_CR32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1126\/science.1257530","volume":"346","author":"N Iijima","year":"2014","unstructured":"Iijima, N. & Iwasaki, A. A local macrophage chemokine network sustains protective tissue-resident memory CD4 T cells. Science 346, 93\u201398 (2014).","journal-title":"Science"},{"key":"460_CR33","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1017\/S0950268800048019","volume":"105","author":"KA Callow","year":"1990","unstructured":"Callow, K. A., Parry, H. F., Sergeant, M. & Tyrrell, D. A. J. The time course of the immune response to experimental coronavirus infection of man. Epidemiol. Infect. 105, 435\u2013446 (1990).","journal-title":"Epidemiol. Infect."},{"key":"460_CR34","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/jmv.1890130208","volume":"13","author":"SE Reed","year":"1984","unstructured":"Reed, S. E. The behaviour of recent isolates of human respiratory coronavirus in vitro and in volunteers: evidence of heterogeneity among 229E-related strains. J. Med. Virol. 13, 179\u2013192 (1984).","journal-title":"J. Med. Virol."},{"key":"460_CR35","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41577-020-00451-5","volume":"20","author":"A Fontanet","year":"2020","unstructured":"Fontanet, A. & Cauchemez, S. COVID-19 herd immunity: where are we? Nat. Rev. Immunol. 20, 583\u2013584 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"460_CR36","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.02107-20","author":"A Addetia","year":"2020","unstructured":"Addetia, A. et al. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate. J. Clin. Microbiol. https:\/\/doi.org\/10.1128\/jcm.02107-20 (2020).","journal-title":"J. Clin. Microbiol."},{"key":"460_CR37","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.14.20151126","author":"A Wajnberg","year":"2020","unstructured":"Wajnberg, A. et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2020.07.14.20151126 (2020).","journal-title":"medRxiv"},{"key":"460_CR38","doi-asserted-by":"publisher","DOI":"10.1101\/2020.08.11.20171843","author":"LB Rodda","year":"2020","unstructured":"Rodda, L. B. et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2020.08.11.20171843 (2020).","journal-title":"medRxiv"},{"key":"460_CR39","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","volume":"26","author":"Q-X Long","year":"2020","unstructured":"Long, Q.-X. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 26, 1200\u20131204 (2020).","journal-title":"Nat. Med."},{"key":"460_CR40","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2026116","author":"DF Gudbjartsson","year":"2020","unstructured":"Gudbjartsson, D. F. et al. Humoral immune response to SARS-CoV-2 in Iceland. New Engl. J. Med. https:\/\/doi.org\/10.1056\/nejmoa2026116 (2020).","journal-title":"New Engl. J. Med."},{"key":"460_CR41","doi-asserted-by":"crossref","unstructured":"Stephens, D. S. & McElrath, M. J. COVID-19 and the path to immunity. JAMA 324, (2020).","DOI":"10.1001\/jama.2020.16656"},{"key":"460_CR42","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1126\/science.abc6810","volume":"369","author":"T Britton","year":"2020","unstructured":"Britton, T., Ball, F. & Trapman, P. A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2. Science 369, 846\u2013849 (2020).","journal-title":"Science"},{"key":"460_CR43","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.27.20081893","author":"MGM Gomes","year":"2020","unstructured":"Gomes, M. G. M. et al. Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity threshold. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2020.04.27.20081893 (2020).","journal-title":"medRxiv"},{"key":"460_CR44","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1007\/s11538-012-9749-6","volume":"74","author":"JC Miller","year":"2012","unstructured":"Miller, J. C. A note on the derivation of epidemic final sizes. Bull. Math. Biol. 74, 2125\u20132141 (2012).","journal-title":"Bull. Math. Biol."},{"key":"460_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.09.038","author":"CR Moderbacher","year":"2020","unstructured":"Moderbacher, C. R. et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell https:\/\/doi.org\/10.1016\/j.cell.2020.09.038 (2020).","journal-title":"Cell"},{"key":"460_CR46","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.immuni.2020.08.003","volume":"53","author":"M Bunders","year":"2020","unstructured":"Bunders, M. & Altfeld, M. Implications of sex differences in immunity for SARS-CoV-2 pathogenesis and design of therapeutic interventions. Immunity 53, 487\u2013495 (2020).","journal-title":"Immunity"}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41577-020-00460-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-020-00460-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-020-00460-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T17:37:38Z","timestamp":1633628258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41577-020-00460-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["460"],"URL":"https:\/\/doi.org\/10.1038\/s41577-020-00460-4","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.738792507.793579431","asserted-by":"object"}]},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,6]]},"assertion":[{"value":"25 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.S. is a consultant for Gritstone, Flow Pharma, Merck and Avalia. S.C. is a consultant for Avalia and JPMorgan. M.L. discloses honoraria\/consulting from Merck, Affinivax, Sanofi-Pasteur and Antigen Discovery; research funding (institutional) from Pfizer; and unpaid scientific advice to Janssen, AstraZeneca, 1DaySooner and Covaxx (United Biomedical). Y.H.G. discloses consulting from Merck and Quidel; and research funding (institutional) from Pfizer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}